Questioning When to Start Immunotherapy for Patients With Oncogenic Drivers

May 21, 2020

Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.

BMI May Stratify Clinical Trials to Measure Survival With Immunotherapy in NSCLC

May 18, 2020

A study found correlation between body mass index in patients with non–small cell lung cancer treated with atezolizumab and improved survival outcomes.

Exploring Biomarkers for Immunotherapy Treatment in Lung Cancer

May 13, 2020

Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.

Doctors Debate: Should Immunotherapy Be Given Before or After Surgical Resection in Locally Advanced NSCLC?

April 22, 2020

“We don’t have a good understanding of why some patients have a robust response to immunotherapy and others do not. That’s important, not only in terms of selecting patients but also in terms of the therapy approach. This is one reason why clinical trials are incredibly important.”

Discussing the Evolution of Immunotherapy in Lymphomas

April 21, 2020

Joshua Brody, MD, discusses how he sees the use of immunotherapy evolving in coming years.

Expert Addresses Role of CAR T-Cell Therapy in Solid Tumors

April 14, 2020

Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.

Compelling Sacituzumab Govitecan Data in mTNBC Add to FDA Approval Hopes

April 07, 2020

Treatment with sacituzumab govitecan resulted in “compelling evidence of efficacy” in patients with metastatic triple-negative breast cancer, leading to an early halt of the phase III ASCENT study, announced Immunomedics in a press release.

ZUMA-2 Update: KTE-X19 Induced Durable Remission in R/R Mantle Cell Lymphoma

April 03, 2020

Durable remissions were elicited with KTE-X19 in a majority of patients with relapsed or refractory mantle cell lymphoma, according to the updated results from the ZUMA-2 trial published in the New England Journal of Medicine. The treatment did, however, cause serious adverse events that were consistent with known toxicities of chimeric antigen receptor T-cell therapy.

CAR T Cells Push Forward in Solid Tumors Following Positive Results in Hematology

April 01, 2020

In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed the expansion of chimeric antigen receptor T-cell research in the solid tumor space and the challenges researchers will need to overcome in order to make this therapy effective for patients outside of the hematologic treatment landscape.

Immunotherapy Induces Responses in Subtypes of Sarcomas

March 28, 2020

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.